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Abstract
Background: HMGA2 is an architectonic transcription factor abundantly expressed during embryonic and fetal development
and it is associated with the progression of malignant tumors. The protein harbours three basically charged DNA binding
domains and an acidic protein binding C-terminal domain. DNA binding induces changes of DNA conformation and hence
results in global overall change of gene expression patterns. Recently, using a PCR-based SELEX (Systematic Evolution of
Ligands by Exponential Enrichment) procedure two consensus sequences for HMGA2 binding have been identified.
Methodology/Principal Findings: In this investigation chromatin immunoprecipitation (ChIP) experiments and bioinfor-
matic methods were used to analyze if these binding sequences can be verified on chromatin of living cells as well.
Conclusion: After quantification of HMGA2 protein in different cell lines the colon cancer derived cell line HCT116 was
chosen for further ChIP experiments because of its 3.4-fold higher HMGA2 protein level. 49 DNA fragments were obtained
by ChIP. These fragments containing HMGA2 binding sites have been analyzed for their AT-content, location in the human
genome and similarities to sequences generated by a SELEX study. The sequences show a significantly higher AT-content
than the average of the human genome. The artificially generated SELEX sequences and short BLAST alignments (11 and
12 bp) of the ChIP fragments from living cells show similarities in their organization. The flanking regions are AT-rich,
whereas a lower conservation is present in the center of the sequences.
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Introduction
High mobility AT-hook 2 (HMGA2) is a chromatin-associated
protein implicated in the development and progression of benign
and malignant tumors as well as stem cell self-renewal [1,2,3].
Although some single target genes directly regulated by HMGA2
have been identified there is little doubt that it rather acts as a
global chromatin switch than as a transcription factor controlling a
few genes only [4,5,6]. On the other hand, its primary action as a
chromatin-remodeling switch molecule requires a large number of
DNA binding sites throughout the genome which would fit with its
relative abundance e.g. in embryonic stem cells [7,8]. Neverthe-
less, surprisingly little is known about possible patterns of its
binding sites on the chromatin of living cells. Akin to the other
mammalian HMGA proteins HMGA2 is characterized by three
highly basic DNA-binding motifs called AT-hooks. All three AT-
hooks show striking amino acid similarities with each other.
Generally, the minor grooves of AT-rich DNA stretches are
thought to represent suitable binding sites for the AT-hooks [9,10].
Moreover, stable DNA binding apparently requires interacting of
the central AT-hook and either of the two flanking hooks to DNA
[11]. In a recent paper, Cui and Leng [12] have used a SELEX
procedure for the analysis of the interactions of short random
DNA fragments with HMGA2 to delineate consensus sequences
for the binding of AT-hooks. The study has resulted in the
identification of a DNA motif and its derivates strongly supporting
HMGA2 binding but the results were obtained using naked DNA
instead of chromatin fragments and comprehensive data on its
chromatin binding in living cells are missing. Herein, we have
performed a study based on chromatin immunoprecipitation
(ChIP) from living cancer cells to analyze HMGA2 binding sites.
The resulting fragments have been analyzed for a common
binding motif as well as for similarities to the sequences emerging
from the study by Cui and Leng [12].
Results
Isolation of HMGA2 binding sites via ChIP
The first step for characterization of HMGA2 binding sites was
to choose an adequate cell line showing high levels of HMGA2 for
the following ChIP analyses. Therefore, we investigated the
HMGA2 mRNA expression of 14 cell lines and one tissue sample
of human origin. RNA expression of cell line HCT116
(adenocarcinoma of the colon) was up to 3,300-fold elevated in
comparison to sample MM 31 (myometrium). This expression of
HMGA2 mRNA in HCT116 was by far the highest among the cell
lines investigated (Fig. 1). To check these results on the protein
level Western Blot analysis was performed using selected cell lines.
As shown in Figure 2 we detected HMGA2 in three cell lines and
the amount of protein was calculated refering to b-actin as
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of HMGA2 detected in Western Blot analysis was 2.1- (Li14) and
3.4-fold (FTC133) higher. This tendency corresponds to the
relative HMGA2 mRNA expression measured with real-time PCR,
in which HCT116 shows a 3.8-fold (Li14) and 5.6- (FTC133)
higher expression (Fig. 2B).
For this study two basic protocols for ChIP [13,14] have been
optimized for use with HCT116 cells. A flow diagram of the
procedure is provided in Figure S1, and the details are given under
materials and methods. The DNA enrichment within the samples
was measured by real-time PCR and analysis was done by
comparing the data from the immunoprecipitated sample (IP)
against the background signal of the negative control without
antibody (NoAb) to calculate the x-fold enrichment. In Table 1 the
results of five samples used for ChIP followed by cloning of the
DNA fragments are displayed. Average enrichment of the IP
samples was 246-fold. The amplified gene sequence of GAPDH
has no known HMGA2 binding site and served as a control to
evaluate the DNA concentration and enrichment after ChIP.
Furthermore, the enrichment of HMGA2 during ChIP was
confirmed by Western blot analysis (Fig. 3) as revealed by the
presence of HMGA2 in the IP sample but not in the
corresponding supernatant. In contrast, HMGA2 can be detected
in the supernatant of the NoAb control and not in the eluate of the
negative control. The immunoprecipitated DNA fragments were
cloned into pGEM-T easy vector for blue/white screening. 49
clones from ChIP-derived DNA fragments were obtained and
sequenced.
Analysis of immunoprecipitated and sequenced DNA
fragments
All 49 sequences were mapped to single loci in the human
genome using the NCBI BLAST tool (Table 2). Length of ChIP
DNA fragments ranged from 105 bp to 1848 bp with an average
length of 517 bp. 23 of the cloned sequences were located
intergenic and 23 intragenic. The remaining fragments matched to
an unplaced genomic region not assigned to a chromosome until
now. Table 2 displays the genes which are located upstream or
downstream within the flanking regions of the 23 intergenic
sequences, with a distance ranging from approximately 500 bp to
2000 kb. From a total of the 23 intragenic sequences seven were
located within the first intron and three in the second intron. The
remaining 12 sequences were assigned to various other introns,
except for one fragment located in the second exon of a gene.
Detailed sequences are listed in Table S1.
For further analysis we compared our ChIP fragments with
known binding sites, as predicted by Cui and Leng [12]. Two
consensus sequences (59-ATATTCGCGAWWATT-39 and 59-
ATATTGCGCAWWATT-39, where W represents A or T) have
Figure 1. Relative expression of HMGA2 in different samples.
Origin of the various human cell lines and fresh sample: MCF 7 (mamma
carcinoma), MM 31 (myometrium); MRI-H215, MRI-H196 and MRI-H186
(cervical carcinoma); Ad 211 (pleomorphic adenoma); NB-4 (promyelo-
cytic leukemia); FTC133 and FTC238 (follicular thyroid carcinoma); TPC-1
(papillary thyroid carcinoma); Li14 (lipoma); FRO (anaplastic thyroid
carcinoma); WRO (follicular carcinoma); supT1 (T cell lymphoblastic
lymphoma); HCT116 (colon carcinoma).
doi:10.1371/journal.pone.0018837.g001
Figure 2. Western blot analysis of HMGA2 in different cell lines.
(A) Expression of HMGA2 in three cell lines was determined using b-
actin as endogenous control. (B) Comparison of HMGA2 mRNA
expression and HMGA2 protein expression in exemplary cell lines.
doi:10.1371/journal.pone.0018837.g002
Table 1. x-fold enrichment of the chromatin
immunoprecipitated samples measured with GAPDH primers.
Sample Average Ct-value Ct
NoAb-Ct
IP x-fold Enrichment
32 IP 29.85 8.55 374.29
32 NoAb 38.39
33 IP 30.76 6.25 76.21
33 NoAb 37.01
35 IP 30.37 8.86 464.65
35 NoAb 39.23
36 IP 29.49 6.97 125.37
36 NoAb 36.46
37 IP 29.84 7.57 190.15
37 NoAb 37.41
doi:10.1371/journal.pone.0018837.t001
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the described consensus sequences, to analyze whether these
putative binding sites are part of our ChIP sequences obtained
herein. None of the consensus sequences was detected in the
sequences revealed by ChIP. Next, the ChIP-generated fragments
were compared with sequences containing lower constraint as
identified by the SELEX [12] study. This lower constraint
expanded the described HMGA2 binding sequences to 4,096
binding sites within the human genome. With a Perl program
using a pattern match representing the 4,096 possibilities and
NCBI BLAST standalone tool the sequences were scanned for
possible HMGA2 binding sequences. Again, none of these putative
HMGA2 binding sites was detected in sequences resulting from
ChIP.
Because none of the sequences for HMGA2 binding described
by Cui and Leng [12] matched within the isolated ChIP
fragments, we scanned the human genome for the putative
consensus sequences generated in the above mentioned SELEX
study. For this the Perl program and the NCBI BLAST tool
adapted to short sequences were used. Only six matches in the
whole genome can be found for the conserved possible HMGA2
binding sites described by Cui and Leng [12] (NCBI refseq human
genomic sequences build 36). If the consensus is extended to the
4,096 possibilities, 27,455 matches exist (Human genome NCBI
refseq sequences Build 36). Thus, a possible binding site for
HMGA2 would occur on average every 104,565 bp. In compar-
ison to the theoretically expected occurrence of such a 15 bp
sequence pattern (every 262,144 bp in the human genome) the
consensus is 2.5 times more often attendant.
Because HMGA2 is supposed to bind to the minor groove of
AT-rich sequences [15], the sequences identified by the ChIP
experiments have been analyzed for their AT-content. Approxi-
mately three-fourth of the sequences had AT-content exceeding
the average of 59% in the human genome [16] with 20% of them
even being highly AT-rich exceeding 70%. The AT-content in the
deduced ChIP sequences was compared to the distribution in the
human genome (NCBI refseq sequences Build 36), for that
purpose the whole genome was split into pieces of 500 bp and the
AT-content was determined (Fig. 4). For analysis of statistical
significance and due to non-normality of the AT-distribution in
the human genome [16] the Wilcoxson rank sum test as non-
parametric alternative has been used. The distribution of the AT-
content in the ChIP DNA sequences discribed herein is
significantly higher than it would be expected in random
fragments of the human genome (p,0.0012) (W=105561580).
The cloned sequences were analyzed for the presence of any
conserved sequences using the NCBI BLAST tool. This analysis
shows a high rate of matches. These sequences have a significant
higher AT-content compared to the human genome
(W=1169693292, p-value,2.2e
216, Wilcoxon rank sum test)
and to the ChIP-isolated sequences themselves (W=11787, p-
value=1.561e
205, Wilcoxon rank sum test). All sequences show
multiple AT-stretches except for clone 25 and 49 containing only
one AT-stretch. To identify further similarities between these
BLAST matching sequences the 11 and 12 bp matches were
adjusted manually from redundancies and used to create a
sequence logo (WebLogo, http://weblogo.berkeley.edu/logo.cgi).
In both cases the logo shows a higher AT-content in the flanking
regions and no specificity in the middle of the sequence (Fig. 5).
Discussion
A crucial question in field of gene regulation is where and to
what extent transcription factors bind to DNA. This study is
focused on the architectonic transcription factor HMGA2 which is
abundantly expressed during embryonic and fetal development,
whereas expression in normal fully differentiated adult cells is very
low or even absent. This is the first time HMGA2 binding on
chromatin in living cells is determined by ChIP analysis. The
advantage of this method is that there is no need to prior
identification of target genes regulated through binding of
HMGA2. Furthermore, regulatory regions can be revealed wether
they are located at promotors, introns or even distant enhancer
elements.
In our study we selected a cell line with abundant expression of
HMGA2 but this is not necessarily associated with malignant
cellular behavior because, e.g. embryonic stem cells show a high
level of HMGA2 associated with differentiation and cell
proliferation during embryonic development [8]. Comparing the
colon carcinoma cell line HCT116 with the thyroid carcinoma cell
line FTC133 a drastical overexpression of HMGA2 both in the
mRNA and the protein level compared to the myometrium was
noted, the relationship between these two cell lines was in a
comparable rang, i.e. HCT116 had a 5.6-fold higher expression of
HMGA2 mRNA than FTC133 and a 3.4-fold higher expression
on the protein level.
We compared the sequences of the DNA fragments obtained to
results of a previously performed SELEX analysis on protein-free
DNA [12]. These sequence motifs which should bind HMGA2 as
described by Cui and Leng 2007 [12] have not been found in the
DNA fragments revealed by ChIP. There are two possible
explanations for the absence of corresponding sequences in the
fragments identified by ChIP. First, HMGA2 proteins are not only
interacting with DNA but also with a variety of other DNA
binding and chromatin binding proteins like APEX1 (APEX
nuclease (multifunctional DNA repair enzyme) 1) [17] and E4F1
(E4F transcription factor 1) [18]. If not distinguished from the
highly similar HMGA1a and HMGA1b proteins, which is
common in the literature, the HMGA proteins have a lot of
molecular partners as transcription factors and other DNA binding
proteins (reviewed in [19]). Considering this facts together with the
direct involvement of HMGA2 in base excision repair with own
enzymatic lyase activity [17] it is not likely that HMGA2 is binding
DNA in a specific manner. Especially for the function in excision
repair a specific binding site seems counterproductive to the
occurrence of mutations only by chance not at specific sites.
The second possible explanation for the absence of similarities
between the SELEX sequences and the ChIP DNA fragments is,
that the occurrence of the consensus sequences for HMGA2
binding described by Cui and Leng [12] is rare and the statistics of
appearance of a 15 bp sequence (approximately three times in the
human genome, with the ambiguity approximately 18 times)
implicates that these consensus sequences are of limited biological
Figure 3. Western blot analysis of HMGA2 in ChIP samples. The
analysis shows an enrichment of HMGA2 in the IP sample but not in the
corresponding supernatant. No HMGA2 is detectable in the eluate of
the NoAb control because HMGA2 remains in the supernatant of the
non-immunoprecipitated sample.
doi:10.1371/journal.pone.0018837.g003
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Clone Length [bp] AT [%] Localization Gene Symbol Location to Gene Distance to Gene
41 105 61 1p35 PTPRU upstream 180 kb
28 403 68 1q25 SEC16B downstream 70 kb
3 440 61 1q25.1 TNR intron 1 -
23 253 63 1q31 KCNT2 downstream 1000 kb
14 652 69 1q31.1 FDPSL1 downstream 300 kb
27 1017 57 1q42 CDC42BPA intron 21 -
8 715 68 2p13.3 GKN3P intron 1 -
2 373 65 2p24.1 WDR35 intron 34 -
29 316 47 2q31 HOXD10 exon 2 -
48 1612 54 3p21 LARS2 intron 13 -
45 1592 59 3p22 STAC downstream 170 kb
44 234 70 3q26.1 SI downstream 25 kb
49 157 52 3q26.1 KPNA4 intron 1 -
40 171 62 4p15.1 ARAP2 downstream 2000 kb
16 395 63 4q31.1 CLGN upstream 500 bp
12 981 69 4q32.3 SPOCK3 upstream 300 kb
10 350 73 4q34.3 RPL19P8 downstream 15 kb
39 561 60 5p14 PRDM9 downstream 117 kb
32 1080 61 6p22 DCDC2 intron 2 -
22 574 67 6q16 TSG1 upstream 113 kb
20 574 67 6q22 NKAIN2 intron 1 -
6 639 62 6q22.31 MAN1A1 downstream 830 kb
35 233 68 6q23 VNN3 upstream 900 bp
34 105 74 7q22 RELN intron 33 -
17 323 58 7q36.1 ACTR3C upstream 9 kb
4 492 72 8q21.12 PKIA upstream 220 kb
7 219 72 8q23.2 PKHD1L1 intron 16 -
13 161 72 9q21.12 ALDH1A1 upstream 90 kb
36 276 52 9q22 COL15A1 intron 1 -
30 765 50 9q34 ENG intron 8 -
46 180 69 10p11.2 CCDC7 downstream 32 kb
43 300 60 10p13 FAM107B intron 2 -
15 305 71 10q21.3 JMJD1C intron 22 -
5 1848 67 13q32.3 FGF-14 intron 1 -
11 363 71 14q21.3 RPL10L downstream 350 kb
24 142 64 14q32 PPP4R4 intron 2 -
42 695 52 17q21 PLEKHM1 upstream 3 kb
33 1220 61 17q22 MBTD1 intron 6 -
19 508 51 17q23.3 RGS9 intron 19 -
18 495 64 18p11.22 PPP4R1 intron 23 -
31 412 60 18q21 STARD6 upstream 149 kb
26 287 64 19q12 ZNF99 downstream 25 kb
47 359 66 19q13.1 FCGBP intron 3 -
9 511 66 20q13.11 PTPRT intron 1 -
1 500 56 20q13.13 NFATC2 downstream 6.5 kb
25 235 46 21q22 RUNX1 intron 5 -
21 201 54 *
37 633 62 *
38 388 79 *
*Unplaced genomic region.
doi:10.1371/journal.pone.0018837.t002
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chromatin-remodelling switch HMGA2 is supposed to require a
large number of DNA binding sites throughout the genome. This
is consistent with the observations of relative abundance of
HMGA2 in embryonic stem cells by Li et al. [7,8]. Therefore, the
rare occurrence of the consensus sequences has to be explained.
Besides the possibility of artificial binding in the SELEX
experiments the statistical 2.5 fold overrepresentation of the
extended HMGA2 consensus sequences versus the representation
of such sequences only by chance in the human genome points to a
possible other explanation. The consensus motif described by Cui
and Leng [12] is efficiently binding HMGA2 but in vivo this
binding is maybe irrelevant. The binding might be too strong for
purposes of dynamic regulation which is required for the proper
activity of HMGA2.
The AT-content of the sequences generated by ChIP is
significantly higher than the average of the human genome. This
confirms the hypothesis that HMGA2 binds to AT-rich sequences.
It therefore seems feasible to speculate that a motif with central
GC bases and flanking AT bases is the possible target of HMGA2.
The analysis of the DNA fragments among each other shows a
multitude of matches for conserved AT-stretches. All sequences
but two contain multiple AT-stretches. A possible explanation for
these two sequences having only one AT-stretch is that HMGA2
does not necessarily need DNA to interact with because it can bind
to DNA- or chromatin binding proteins as well [17,18]. To
identify further similarities between these BLAST matching
sequences, 11 bp and 12 bp matches were used exemplarily to
create a sequence logo. Interestingly, the high AT-content in the
flanking sequences resembles the pattern of the SELEX sequences
presented by Cui and Leng [12]. This pattern has a central of 4
GC-rich bases flanked by AT-rich sequences. It is well known, that
HMGA2 is a DNA binding protein that specifically recognizes the
minor groove of AT-rich DNA sequences. One turn in DNA
consists of approximately 10 bp and thus both presented patterns
fit to the HMGA2 AT-hook composition and the winding of the
DNA molecule.
HMGA2 is able to regulate certain genes via binding to
promoter or enhancer regions, which are located upstream or
downstream to the target gene, as well as intronic e.g. in case of
the IMP2 gene [20,21]. Except for one sequence all possible
binding sites were assigned to non-coding regions. Some of the
genes identified to be located close to the generated ChIP DNA
fragments play an important role in different types of cancer with
high HMGA2 expression. RELN and ALDH1A1 are expressed in
prostate cancer [22,23], ENG [24], SI [25], FCGBP [26] and
PTPRT [27] are associated with colonic tumors. HOXD10 [28]
and MAN1A1 [29] show an up-regulated gene expression in breast
cancer. The RPL10L gene is related to ovarian cancer [30] and
JMJD1C plays an essential role in embryogenesis and carcino-
genesis [31]. A functional relation between the oncofetal HMGA2
and the above mentioned genes is feasible and as a transcription
factor HMGA2 is able to influence many different regulatory
processes [32]. It remains to be elucidated, if HMGA2-binding is
directly related to the up- or down-regulation of expression in this
certain cases either through directly binding to DNA or in a
complex with other proteins.
To the best of our knowledge this is the first approach to
characterize possible HMGA2 binding sites in the chromatin of
living cells by ChIP and cloning. Via protein-DNA binding
HMGA2 plays important roles in tumor growth and stem cell-
renewal. The possibility to screen, localize, and characterize the
whole human genome for sequences bound to HMGA2, can help
to understand in which way HMGA2 is associated with different
biological processes.
Materials and Methods
Ethics Statement
The use of the human myometrium sample for this study was
approved by the local medical ethics committee and followed the
Figure 4. Histogram of the AT-content in the human genome
and the ChIP DNA sequences. The whole human genome was split
into pieces of 500 bp and AT-content was determined and compared to
the AT-content of the sequences revealed by ChIP with HMGA2-
antibody. The Wilcoxson rank sum test shows that the AT-content in the
ChIP DNA sequences is significantly higher than in the human genom
(p,0.0012).
doi:10.1371/journal.pone.0018837.g004
Figure 5. Sequence analysis of the concerted BLAST align-
ments of the detected ChIP sequences. The sequence logo was
created by 12 bp long BLAST alignments. Sequence conservation,
measured in bits of information, is illustrated by the height of stacking
of the four letters for each position in the binding sites. The relative
heights are proportional to their frequencies shown in the 134 BLAST
sequences. The sequence logo was generated by WebLogo (available at
http://weblogo.berkeley.edu/logo.cgi).
doi:10.1371/journal.pone.0018837.g005
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informed consent for clinical procedure and research use of the
tissues.
Cell culture
14 human cell lines and one sample of fresh tissue were
examined in this study: MCF 7 (mamma carcinoma) [33], MM 31
(myometrium); MRI-H215, MRI-H196 and MRI-H186 (cervical
carcinoma) (provided by H. Lo ¨hrke, German Cancer Research
Center, Heidelberg); Ad 211 (pleomorphic adenoma) [34]; NB-4
(promyelocytic leukemia) [35]; FTC133 and FTC238 (follicular
thyroid carcinoma) [36]; TPC-1 (papillary thyroid carcinoma)
[37]; Li14 (lipoma) [38]; FRO (anaplastic thyroid carcinoma) [39];
WRO (follicular carcinoma) [40]; supT1 (T cell lymphoblastic
lymphoma) [41]; HCT116 (colon carcinoma) [42]. They were
cultured in RPMI 1640, TC 199 or McCoy’s 5A medium
supplemented with 10% or 20% fetal bovine serum and 2%
penicillin/streptomycin (all Invitrogen, Karlsruhe, Germany). All
cells were incubated at 37uC in a humidified incubator with 5%
CO2. Sample MM 31 was taken during surgery, immediately
frozen in liquid nitrogen, and stored at 280uC for RNA isolation.
RNA-Isolation
Total RNA was purified from cell lines and the tissue sample
according to the ‘‘RNeasy mini protocol for isolation of total
RNA from heart, muscle and skin tissue’’ (Qiagen, Hilden,
Germany) including on-column DNase I digest and homogeni-
sation with QIAshredder. Following quantification, 5 mgR N A
have been digested a second time with DNaseI (6.75 U) for
15 min at room temperature and a cleanup according to the
RNeasy mini protocol was performed to remove possible
contaminating DNA completely.
Chromatin Immunoprecipitation
Approximately 1610
7 HCT116 cells were harvested with
TrypLE Express (Invitrogen, Karlsruhe, Germany) and the cell
suspension was transferred into a sterile tube filled with McCoy’s
5A medium. Proteins were crosslinked to the DNA using a final
concentration of 1% formaldehyde for 10 min at room temper-
ature. The formaldehyde was quenched with 0.125 M glycine
(final concentration). After centrifugation the cell pellet was rinsed
with an ice-cold PBS/AEBSF solution and then suspended in
ChIP Lysis Buffer (Santa Cruz, Heidelberg, Germany). The
sample was incubated on ice for 5 min and the pellet was rinsed
with an ice-cold PBS/AEBSF solution again. For sonication, the
pellet was suspended in 300 ml ChIP Lysis Buffer High Salt (Santa
Cruz, Heidelberg, Germany). Fragmentation of the DNA was
performed on ice, first to isolate and break down the nuclei and
then to fragment the DNA (size 200–500 nucleotides). The
parameters were 10 s pulse on and 20 s pulse off for 37.5 min with
a Bandelin sonicator HD 3200 plus (Bandelin, Berlin, Germany).
The sheared chromatin was cleared by centrifugation at 4uC
(10 min at 10,6216g).
Magnetic Dynabeads protein G (Invitrogen, Karlsruhe, Ger-
many) were prepared before usage following the manufacturer’s
instruction. To reduce the background signal a preclearing step
was performed. 100 ml beads were added to the sample and the
suspension was incubated for 30 min at 4uC with rotation. The
supernatant was transferred and divided into two fractions (IP and
NoAb). 4 mg anti-HMGA2 antibody (Santa Cruz, Heidelberg,
Germany) were added to the IP sample, the fraction without
antibody (NoAb) served as a negative control. Both fractions were
incubated over night at 4uC on a rotator. To avoid unspecific
interactions between DNA and beads, Dynabeads protein G were
rotated with 22.2 mg salmon sperm DNA for 30 min at 4uC before
use. After this second preclearing step, the IP and NoAb fractions
were incubated on a rotator for 2 h at 4uC each with 50 ml of the
blocked Dynabead suspension. The immune complexes were
washed two times with 1 ml ChIP Lysis Buffer, four times with
ChIP Lysis Buffer High Salt and ChIP Wash Buffer (Santa Cruz)
and once with 16TE buffer (10 mM Tris base, 1 mM EDTA). All
washing steps were carried out at 4uC. To reverse crosslinks the
Dynabeads protein G were suspended in 150 ml SDS elution
buffer (1% SDS, 0.1 M NaHCO3) and incubated in a shaking
water bath for 2 h at 67uC. The supernatants were transferred into
new 2 ml plastic tubes and incubated with 5 mg Proteinase K
(Qiagen, Hilden, Germany) for another 2 h at 67uC. To avoid
precipitation during the DNA isolation the samples were diluted
1:2 with H2O. The DNA was isolated using the QIAquick PCR
Purification Kit (Qiagen, Hilden, Germany) following the
manufacturer’s instructions.
SDS-PAGE and Western Blotting
The protein concentration was measured with the BCA Protein
Assay Kit (Pierce, Bonn, Germany) 15 mg of protein obtained from
each sample were used for SDS-PAGE in a X-Cell Sure Lock
Mini-Cell apparatus (Invitrogen, Karlsruhe, Germany) and
transferred to a nitrocellulose membrane with the Fastblot 33
system (Biometra, Go ¨ttingen, Germany). The membrane was
blocked with 5% BSA over night and incubated with rabbit
polyclonal anti-HMGA2 antibody (1:3000, Biocheck, Foster City,
USA) and mouse monoclonal anti-b-actin (1:7500, Novus
Biologicals, Cambridge, United Kingdom) for one hour. Second
antibodies were alkaline phosphatase-bovine anti-rabbit IgG
(1:3750, Sante Cruz, Heidelberg, Germany) and alkaline phos-
phatase-goat anti-mouse IgG (1:7500, Invitrogen, Karlsruhe,
Germany). The detection of b-actin was used as an internal
control to confirm equivalent total protein loading. Relative
HMGA2 protein expression was determined by band intensities
with the ImageJ program.
For determination of protein expression in the ChIP samples,
supernatants of samples after DNA-protein-antibody-bead-com-
plex formation (IP and NoAb) and samples before Proteinase K
digestion (IP and NoAb) were taken. Proteins were separated by
SDS-PAGE as described by Laemmli [43] using the Minigel-
System Protean II and transferred to a polyvinyl difluoride
membrane using the Mini-Transblot System (Biorad, Munich,
Germany). The membrane was blocked with TBS-T buffer
(10 mM Tris-HCl, 150 mM NaCl, 1% Tween-20) containing
5% skimmed milk and incubated with rabbit polyclonal anti-
HMGA2 antibody (1:800, Santa Cruz, Heidelberg, Germany) for
one hour. The second antibody-step was performed with the
alkaline phosphatase-goat anti-rabbit IgG (1:5000, Invitrogen,
Karlsruhe, Germany) and bands were visualized by adding BCIP/
NBT substrate (Roche Diagnostics, Mannheim, Germany).
Real-time PCR
All real-time PCRs were run on an ABI Prism 7300 Sequence
Detection System (Applied Biosystems, Darmstadt, Germany). For
Quantification of HMGA2 250 ng total RNA were reverse
transcribed with 200 units of M-MLV Reverse Transcriptase
(Invitrogen, Karlsruhe, Germany) and 150 ng random hexamers
(Fisher Scientific, Schwerte, Germany) according to the manufac-
turer’s instructions. The relative quantification method was carried
out using 18S rRNA as endogenous control (forward primer 59-
GGA TCC ATT GGA GGG CAA GT-39; reverse primer 59-
AAT ATA CGC TAT TGG AGC TGG AAT TAC-39 and probe
59-6-FAM-TGC CAG CAG CCG C-MGB-39) [44]. The samples
Analysis of DNA Binding Sites
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expression level of 18S rRNA. HMGA2 (Assay Hs00171569_m1,
Applied Biosystems) and 18S rRNA expression analyses were
performed in triplicate in a total volume of 20 ml using 2 ml of each
cDNA corresponding to 25 ng of total RNA. The expression of
the endogenous control 18S rRNA showed only a slight variation
in all the samples, the mean Ct value was 8.1760.21.
IP fragments were analyzed in triplicates starting with 3 mlo f
template DNA. The enrichment of DNA in the samples (IP, NoAb)
was determined by amplification of GAPDH. The sequences for
GAPDH were 5_-6-FAM-AAA GAG CTA GGA AGG ACA GGC
AAC TTG GC-TAMRA-3_ for the fluorescent probe, 5_-CCC
CAC ACA CAT GCA CTT ACC-3_ for the forward primer, and
5_-CCT AGT CCC AGG GCT TTG ATT-3_ for the reverse
primer (Operon, Cologne, Germany). PCR condition were 50uC
for 2 min, 95uC for 10 min and 50 cycles of 95uC for 15 s and 60uC
for 1 min. Results were calculatedby subtractingthe Ct-value of the
sample from the corresponding NoAb control, followed by2
(NoAb-IP)
to evaluate the x-fold higher amount of starting material of the
sample applied in the real-time PCR.
Cloning of immunoprecipitated products
The ChIP-generated DNA fragments were A-tailed and ligated
into the pGEM-T easy vector (Promega, Mannheim, Germany)
with T4 ligase at 4uC over night. The transformation was carried
out according to the manufacturer’s protocol with 100 ml
Escherischia coli DH5a competent cells. 150 ml respectively 200 ml
of the transformation culture were plated onto AIX-plates and
incubated over night at 37uC. Plasmid DNA was isolated with the
QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany) following
the manufacturer’s protocol.
In silico data analysis
Clones were sequenced by Eurofins MWG Operon (Ebersberg,
Germany). After revising with the Lasergene software, a BLAST
search of the human genome database at NCBI was performed to
locate the sequences.
For identifying the consensus sequences in the human genomic
sequences (NCBI refseq build 36) Perl (www.perl.org) with
implemented Bio-Perl Modules [45] has been used. The possible
genomic binding sequences have been identified by pattern
matching. Specific sequences have been analyzed also using
BLAST [46] adjusted to short sequences (Program=blastn, Word
size=7, Expect Value=100, Filter=disabled). For statistical
analysis the statistics software R (www.r-project.org) has been
used. The sequence logo was generated by WebLogo (http://
weblogo.berkeley.edu/logo.cgi).
Supporting Information
Figure S1 Scheme of the HMGA2 chromatin immuno-
precipitation cloning procedure. Cells were crosslinked with
formaldehyde to preserve the structure of chromatin and proteins.
After lysis and sonication the fragmented DNA was immunopre-
cipitated with a HMGA2-antibody. For Western Blot analysis
aliquots were taken after immunoprecipitation. Crosslinks were
reversed in the rest of the samples, DNA was eluted and
enrichment of ChIP DNA fragments was measured by real-time
PCR. ChIP DNA fragments of the remaining samples were cloned
into a vector, sequenced and analyzed.
(TIF)
Table S1 Sequences of the cloned fragments.
(XLS)
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